Additionally, many CMT mutations lead to protein dysfunction or toxic gain-of-function; thus, Tanshinone I’s neuroprotective effects may extend beyond symptom relief by blocking the interaction between the CMT AlaRS mutant and Nrp1, fundamentally improving CMT pathology. The gene discussed is NRP1; the disease is Charcot-Marie-Tooth disease.